Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients.
about
Management of hyperphosphataemia in chronic kidney disease: summary of National Institute for Health and Clinical Excellence (NICE) guidelineKlotho, phosphate and inflammation/ageing in chronic kidney diseaseVascular calcification: When should we interfere in chronic kidney disease patients and how?Stop chronic kidney disease progression: Time is approachingPlasma p-cresol lowering effect of sevelamer in peritoneal dialysis patients: evidence from a Cross-Sectional Observational StudyPhosphate binders in chronic kidney disease: a systematic review of recent data.Associations between the duration of dialysis, endotoxemia, monocyte chemoattractant protein-1, and the effects of a short-dwell exchange in patients requiring continuous ambulatory peritoneal dialysis.Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infectionSevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.Persistent immune activation in chronic HIV infection: do any interventions work?Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic reviewThe gut microbiome, kidney disease, and targeted interventions.Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection.Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective.Pathophysiology and management of cardiovascular disease in patients with HIVSerious Non-AIDS events: Immunopathogenesis and interventional strategies.Hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy.Hyperphosphataemia: treatment options.Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease.The effects of non-calcium-based phosphate binders versus calcium-based phosphate binders on cardiovascular calcification and bone remodeling among dialysis patients: a meta-analysis of randomized trials.Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV InfectionIntestinal Barrier Disturbances in Haemodialysis Patients: Mechanisms, Consequences, and Therapeutic Options.The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.The gut-kidney axis in chronic renal failure: A new potential target for therapy.Strategies to limit immune-activation in HIV patients.Lanthanum carbonate delays progression of coronary artery calcification compared with calcium-based phosphate binders in patients on hemodialysis: a pilot study.FGF23 and inflammationGastrointestinal complications induced by sevelamer crystals.Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremiaEndotoxin binding by sevelamer: potential impact on nutritional status.Comparison of sevelamer and calcium carbonate on endothelial function and inflammation in patients on peritoneal dialysis.Plasma p-cresol lowering effect of sevelamer in non-dialysis CKD patients: evidence from a randomized controlled trial.Clinical factors associated with serum copper levels and potential effect of sevelamer in hemodialysis patients.Phosphate control in reducing FGF23 levels in hemodialysis patients
P2860
Q26866391-B6C3667E-9BBF-4DB4-BF88-E2E779F5799FQ27013965-D18E6D22-6BE0-470B-AECF-5A7C2D8DBA08Q28071582-2F1C4019-72D7-4CE5-9961-8A94D3187C51Q28078020-83123A7C-F6C6-4525-8A05-DF53EB214900Q28535870-DB431E38-9A95-48E7-9905-DCFAE35CC722Q31039292-B2C634EF-3F86-45E4-A72C-92DC96413F21Q34294329-D787CF24-2FC7-416D-8078-A32AC6FD1BDCQ34430215-C8CBBC82-19FD-4360-B054-D3FE259664E8Q34505136-F709A04F-7AD8-4834-A240-321A8A428B75Q34851102-8BAD2F08-BDEB-4E41-AEC7-735F4155C5F0Q35019709-506286B6-FF6E-47C4-A50C-A1814763AA88Q35042986-5C96EDE1-CBD7-40F5-BB9E-906898192081Q36330954-8ED233F8-C3EC-4303-8367-220955E44DECQ36443804-819FCFDC-319C-4FB7-AD52-96F09B47A805Q37038775-B36C948C-7927-4643-A956-40808F0E28C9Q37418140-4B94D7EA-ACBD-4FA6-8DA3-8E7C35AFBF7CQ38092144-DEB6D31E-F1BC-4ACA-A950-75EDE0732E80Q38102603-99F7CAAA-3AFF-44F9-8062-5C54CA31B2CFQ38210438-2F1F4242-FB41-4A43-A63F-F8E7EA1004F2Q38229088-73AC888F-6DC5-4068-8ECE-AE599BF241C5Q38749963-A01D2109-053C-44B1-9F3E-B384B488654DQ38757951-87802F0E-5DA5-4EC5-9974-782E9B58A750Q38819231-C598954C-F403-49AF-989D-5196CBC63FD3Q38955879-F4841AFE-68B2-4343-9639-DACDDE5D83BBQ38985926-CCE092E1-2983-45A4-8252-E7A500190679Q39430387-CA2E5315-2D68-45A8-8DB9-53740E7DC9CBQ40805494-51BDEE96-7F49-4F80-95F4-9242B3865CE9Q41510628-DA7D3764-E68C-4E89-867B-E03434F2B5B8Q42142326-6CCFEDA5-C37A-474F-BD36-46E5BF216C86Q42718522-60D231B4-A030-402F-868A-51605E862C6BQ44853372-0590910C-5D14-45BD-9482-273D6652F70EQ49846193-DC7AE2D4-9171-4BE3-81E1-A9009F79C10DQ51332971-62EC03D9-BED5-42F6-AD76-D72F94475268Q58797979-B39D17DE-28DC-436F-8A7C-0B990F609BD2
P2860
Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Effect of phosphate binders on ...... vels in hemodialysis patients.
@ast
Effect of phosphate binders on ...... vels in hemodialysis patients.
@en
type
label
Effect of phosphate binders on ...... vels in hemodialysis patients.
@ast
Effect of phosphate binders on ...... vels in hemodialysis patients.
@en
prefLabel
Effect of phosphate binders on ...... vels in hemodialysis patients.
@ast
Effect of phosphate binders on ...... vels in hemodialysis patients.
@en
P2093
P2860
P356
P1476
Effect of phosphate binders on ...... vels in hemodialysis patients.
@en
P2093
Carmen Mora-Fernández
Javier Donate-Correa
Javier García-Pérez
Juan F Navarro-González
Mercedes Muros de Fuentes
Violeta Cazaña-Pérez
P2860
P304
P356
10.2215/CJN.01650211
P577
2011-07-22T00:00:00Z